PX1 Research, a US-based supplier of research-grade peptide formulations, has launched a new line of sublingual peptide strips designed for needle-free research applications. The product range includes formulations of Retatrutide, Tirzepatide, and BPC-157, marking a shift in how researchers can access these compounds. The introduction of these dissolving strips provides a non-invasive oral delivery method that may simplify study protocols and expand research possibilities.
The strips are manufactured entirely within the United States under current Good Manufacturing Practice (cGMP) protocols, ensuring stringent quality control throughout production. Each batch undergoes High-Performance Liquid Chromatography (HPLC) purity verification, with results confirming 99% or greater purity across all formulations. A Certificate of Analysis accompanies each product, giving researchers documented evidence of the batch composition before use. This emphasis on domestic manufacturing reflects a commitment to supply chain transparency, which is critical for institutional research projects that require detailed documentation trails.
Among the available formulations, the dissolving Retatrutide strips have drawn particular attention given the compound's presence in ongoing metabolic and weight regulation research. Tirzepatide and BPC-157 are also included, extending the line's coverage to compounds associated with glucose regulation and tissue repair research, respectively. The sublingual delivery format allows the strip to dissolve under the tongue, enabling absorption without the need for needles or syringes. This format addresses a logistical gap for research environments where non-invasive administration methods are required, whether due to protocol specifications, institutional review considerations, or participant-facing study designs.
PX1 Research has positioned these sublingual peptide strips specifically for academic and institutional research contexts. They are not intended for clinical, therapeutic, or human consumption use. Instead, the product addresses demand from researchers who need compounds delivered in a format compatible with non-invasive study designs, where traditional needle-based administration could introduce procedural variables or ethical complications.
The inclusion of BPC-157 alongside GLP-1 receptor agonist-class compounds such as Retatrutide and Tirzepatide signals the line's versatility across research disciplines. Each compound presents distinct molecular properties, and the sublingual strip format has been adapted to accommodate the specific stability and absorption characteristics relevant to each formulation.
The full product line is accessible through PX1 Research, with specific information on dissolving Retatrutide strips available directly on the product page. This launch is expected to impact the research community by offering a more convenient and potentially less invasive option for peptide studies, which could lead to broader adoption in academic and institutional settings.
